Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026
Amphastar reported Q2 revenue of $183.9 million, up 5% year-over-year, while gross margin expanded to 50.8% from 49.6% due to the launch of higher-margin products like ipratropium bromide and iron sucrose. GAAP net income decreased to $30.3 million from $31.0 million in the prior year, though adjusted non-GAAP EPS rose to $0.91 from $0.85, helped by a lower share count.
Key figures
- Eps
- 0.67
- Revenue
- 183903000
- Revenue Yoy
- 5%
- Adjusted eps
- 0.91
- Gross margin
- 50.8%
- Operating income
- 39729000
- Lilly milestone payment
- $100.0 million
- Cash flow from operations 6m
- 99200000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.